Demographic Features and Clinical Course of Patients With Pediatric-Onset Multiple Sclerosis on Newer Disease-Modifying Treatments

Pediatric Neurology（2023）

引用 0|浏览13

暂无评分

摘要

Though limited by relatively short treatment duration with the index DMTs, our data suggest clinical and MRI benefit, as well as high rates of NEDA-2, in a large number of POMS patients, which can be used to guide future studies in this population.

查看译文

关键词

Pediatric multiple sclerosis, Pediatric demyelinating disease, Disease-modifying treatment, Multiple sclerosis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要